Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011849 (diabetes)
 277,896 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 40-year-old patient with a ten-year history of acromegaly had persistent disease despite prior treatment with conventional pituitary radiotherapy and two transsphenoidal hypophysectomies. Initial evaluation showed characteristic acromegalic features, hypertension, amenorrhea, inappropriate diaphoresis, and poorly controlled diabetes mellitus despite isophane insulin suspension daily. Growth-hormone levels were high and did not suppress with glucose load. Treatment with bromocriptine was associated with prompt improvement in glucose intolerance, with elimination of insulin requirement within 72 hours of institutions of this therapy. Blood pressure normalized; inappropriate diaphoresis disappeared. Within three months ovulatory menses were noted to resume for the first time in ten years. There was progressive improvement in the soft-tissue changes of acromegaly. The growth-hormone levels fell within three hours after the first dose of bromocryptine and remained suppressed throughout her six-month course of therapy.
JAMA 1979 Feb 09
PMID:Complete remission of acromegaly with medical treatment. 76 12

Twenty-six patients with necrotizing fasciitis were treated during a nine-year period. Twenty-one (81%) had diabetes mellitus and 19 (73%) had gas in their soft tissues from nonclostridial infection. Although crepitation was found by physical examination in only five patients, roentgenographic examination of the involved site disclosed gas in every patient in whom it was subsequently found at surgery. Previous studies have not used roentgenography to search for soft-tissue gas. The 21 diabetic patients in our series had a mortality of 19%, the lowest yet reported. This suggested that roentgenographic study of cases with fasciitis permits earlier diagnosis and favorably affects outcome.
JAMA 1979 Feb 23
PMID:Necrotizing fasciitis. Importance of roentgenographic studies for soft-tissue gas. 76 45

Glycohemoglobin (GHb) levels were assayed after chromatography on weakly acidic acrylic cationite columns in 167 patients undergoing glucose tolerance test (GTT) and in 105 known diabetics. In 95% of patients with normal GTT levels, the GHb level was in the range of 6.8% to 9.8%. The GHb level was normal in patients with latent diabetes. Glycohemoglobin levels were elevated in patients with poorly controlled diabetes. Even in patients with normal GTT results, GHb levels correlated positively with fasting plasma glucose and glucose tolerance values. In patients with abnormal GTT results or diabetes but not receiving insulin therapy, the correlation between GHb levels and fasting plasma glucose values was significant. The GHb level that distinguished between latent and overt diabetes correlated strongly with the values of fasting plasma glucose and glucose tolerance and reflected changes in the control of diabetes.
JAMA 1979 Mar 02
PMID:Glycohemoglobins and glucose tolerance. 76 68

The results of kidney transplantation in a variety of renal diseases have been analyzed. The diseases causing end-stage kidney failure in recipients were Alport syndrome, amyloidosis, cystinosis, diabetes mellitus, Fabry disease, familial nephritis, gout, medullary cystic disease, oxalosis, and systemic lupus erythematosus. The data indicate that renal transplantation is justifiable and parallels functional results for the more common causes of end-stage renal disease in all but Fabry disease and oxalosis. Although Fabry disease did not recur in any grafted kidney, only three patients have a functioning graft one year after transplantation. From a group of ten patients with oxalosis who received a total of 14 kidneys, only one survives. In no other metabolic disease, except one instance of primary amyloidosis, did the metabolic disease notably affect the transplant as it did in oxalosis.
JAMA 1975 Apr 14
PMID:Renal transplantation in congenital and metabolic diseases. A report from the ASC/NIH renal transplant registry. 80 49

A retrospective record analysis of 112 juvenile-onset diabetics with nephropathy was conducted in order to determine their clinical course. The mean duration of diabetes at the onset of proteinuria was 17.3+/-6.0 years. Early renal failure appeared two years after the onset of protein-uria, and severe renal failure (mean serum creatinine level, 8.5+/-3.9 mg/100 ml) four years after the onset of proteinuria. The mean duration of life after the onset of severe renal failure was six months. The mortality was 53%, with 59% of the deaths attributable to renal failure and 36% to cardiovascular disease. All patients experienced progressive deterioration of renal function as well as the other complications of diabetes, the rate of progression being accelerated toward the end of the course. Juvenile onset diabetics should be considered for renal transplantation before the serum creatinine level reaches 8.5 mg/100 ml.
JAMA 1976 Oct 18
PMID:The clinical course of diabetic nephropathy. 98 37

So-called steroid (glucocorticoids) diabetes developed in 11 (5.5%) of 202 patients receiving 216 renal allografts between December 1963 and June 1974. In three of the 11 patients, hyperosmolar nonketotic syndrome was present at diagnosis; all of the three recovered. Eight of the 11 patients survived with functioning allografts, and only one of the eight requires insulin. Hyperglycemia has been detected in most transplant patients tested in the immediate postoperative period. Factors (including stress from surgery and treatment with drugs such as furosemide) predispose to this condition.
JAMA 1975 Mar 24
PMID:Hyperosmolar nonketotic syndrome and steroid diabetes. Occurrence after renal transplantation. 109 Jul 64

No increased mortality trend attributable to tolbutamide is shown by an analysis of variance on logit-transformed data from the University Group Diabetes Program (UGDP) study. The UGDP's controversial finding of an increased rate with mortality subgrouped by "cardiovascular" causes is confirmed by the Biometric Committee's report, with reservations that failed to include overriding decisive factors. The basic problem is that inspected data set up the hypothesis (the increased cardiovascular mortality), and that the same data were used to test the hypothesis, so that resulting probability values no longer have the usual meaning. The problem was compounded by multiple testing of the data without adjusting the probability levels. When cardiovascular deaths were redefined as myocardial infarcts and sudden deaths, in an attempt to test a proposed etiologic inotropic hypothesis, no significant increase in cardiovascular mortality was found.
JAMA 1975 May 26
PMID:Decisive factors in the tolbutamide controversy. 109 61

Fasting blood glucose (FBG) level and oral glucose tolerance (OGT) were determined in 169 patients within 72 hours of an acute myocardial infarction. Elevated FBG levels were found in 47.5% and a reduced OGT in 72.5%. Of 32 patients who died in the hospital, FBG value was elevated in 72% and the OGT was abnormal in 89%. Of 91 patients who survived longer than six years, the initial FBG level had been elevated in 33%, and the OGT had been abnormal in 67%. Eighty percent of the group with initially raised FBG values had either latent or overt diabetes, while more than 95% of the patients with initially normal FBG values had a normal OGT. Fifty-five percent of the patients with abnormal OGT during myocardial infarction showed normal OGT six years later. The FBG level shortly after an acute myocardial infarction is a better guide to prognosis and to the prediction of subsequent development of diabetes mellitus than the OGT test.
JAMA 1975 Aug 18
PMID:Hyperglycemia during acute myocardial infarction. A six-year follow-up study. 117 80

Clinical coronary heart disease (CHD) occurred in 257 subjects during eight to nine years of follow-up (average, 8 1/2 years) in a prospective study of 39- to 59-year-old employed men. Incidence of CHD was significantly associated with parental CHD history, reported diabetes, schooling, smoking habits, overt behavior pattern, blood pressure, and serum levels of cholesterol, triglyceride, and beta-lipoproteins. The type A behavior pattern was strongly related to the CHD incidence, and this association could not be explained by association of behavior pattern with any single predictive risk factor or with any combination of them.
JAMA 1975 Aug 25
PMID:Coronary heart disease in Western Collaborative Group Study. Final follow-up experience of 8 1/2 years. 117 96

Plasma glucose and glucagon responses to standard meals containing carbohydrate, fat, and protein as in normal diets were studied in 12 subjects with insulin-dependent diabetes and 12 normal subjects. Diabetics had two to three times greater glucagon responses than did normal subjects. Fifteen units of insulin injection did not normalize these excessive glucagon responses, although postprandial hyperglycemia was reduced. Infusion of somatostatin at a dosage of 500 mug/hr prevented glucagon responses and diminished postprandial hyperglycemia by 60%. The combination of insulin and somatostatin caused a progressive fall in plasma glucose levels despite meal ingestion. Somatostatin and insulin, administered subcutaneously in the same syringe, also abolished postprandial hyperglycemia. These studies indicate that excessive glucagon secretion participates in the genesis of diabetic postprandial hyperglycemia. Somatostatin, an inhibitor of glucagon secretion, may thus prove useful as an adjunct to insulin in the treatment of diabetes mellitus.
JAMA 1975 Oct 13
PMID:Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus. 124 53


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>